Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study.
Timothy J WhelanDennis C SgroiKai TreunerYi ZhangTammy PiperRanelle C SalungaIkhlaaq AhmedLucy DoosSarah ThornberKaren J TaylorElena F BrachtelSarah J PirrieCatherine A SchnabelDaniel W ReaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Novel findings demonstrate that BCI (H/I) significantly predicts benefit from extended tamoxifen in HR+ N+ patients with HER2- disease. Moreover, BCI (H/I) demonstrates significant treatment to biomarker interaction across survival outcomes.